LexisNexis® Legal Newsroom
Sunstein Kann Murphy & Timbers LLP: Sentences of Pirate Bay Founders Are Confirmed, But They May Avoid the Brig

By Lisa Tittemore , Chair of the Copyright Practice Group T he jig is up for the brazen anti-copyright activists at The Pirate Bay. In April 2009, the men behind the once-popular Swedish file-sharing website were found guilty of violating Swedish copyright law. As we reported , the Swedish court's...

Sunstein Kann Murphy & Timbers LLP: Pharmaceutical Companies Take Heed — Compulsory Patent License Is Awarded in India

By Thomas Carey and Nancy C. Wilker, Ph.D. As part of the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS), a signatory country can allow someone to produce a patented product or process without the patent owner's consent. The grounds for justifying a grant of a compulsory...

Sunstein Kann Murphy & Timbers LLP: What Did They Know and When Did They Know It? Court Explains How to Distinguish an Inventor from a Pretender

By Meredith Ainbinder , a member of our Litigation Practice Group T he Federal Circuit's opinion in Bard Peripheral Vascular, Inc. v. W.L. Gore & Assocs . has something for everyone: hundreds of millions of dollars in damages, imposition of an ongoing royalty, denial of a permanent injunction...

Sunstein Kann Murphy & Timbers LLP: Overseas Infringement by A Government Contractor: Who, if Anyone, is Liable?

By Thomas Carey , Chair of our Business Practice Group Z oltek Corp. v. United States involved a federal contractor that had apparently infringed a U.S. process patent, engaging in one step of the process in the United States and the other overseas. The international aspect of the matter confounded...

Sunstein Kann Murphy & Timbers LLP: Crazy In Love With Trademarks: What Can Jay-Z and Beyoncé Teach Us About Trademark Filing?

By Steven Abreu , a member of our Trademark Practice Group U.S. trademark applications are matters of public record. When celebrity super-couple Jay-Z and Beyoncé filed a trademark application for their infant daughter's name, Blue Ivy Carter, the public took notice. Are trademarks...

Sunstein Kann Murphy & Timbers LLP: The Inventor’s Burden: Teach Your Best Mode Lest Your Patent be Invalidated

By Samuel J. Petuchowski , a member of our Patent Practice Group I n exchange for the multi-year monopoly that a patent confers, the inventor has to hold up his end of the bargain with the U.S. government: He must teach how his invention works. That way, the public can make use of the invention...

Sunstein Kann Murphy & Timbers LLP: Federal Circuit Thumps Means-Plus-Function Computer Claims Again -- But Not Without Dissent

By Kerry Timbers , Co-chair of the Litigation Practice Group T he Federal Circuit has issued yet another ruling that looks at computer-based means-plus-function claims and finds them wanting. The message is unmistakable: Practitioners must adjust their approach toward writing claims for computer...

Sunstein Kann Murphy & Timbers LLP: Patent Filers: Beware the Ides of March

January 2 to March 15, 2013 will be beyond busy, so planning is essential By Bruce D. Sunstein , a member of our Patent Practice Group The Ides of March in the coming year should be heeded by all patent filers. March 15, 2013 is the last day on which an application can be filed in the U.S. without...

Sunstein Kann Murphy & Timbers LLP: Generic Drugmakers Gain Safe Harbor Protection For Compliance Activities That Occur After FDA Approval

By Isabelle Blundell , a member of our Life Sciences Practice Group E ver since the Hatch-Waxman Act became law in 1984, generic-drug manufacturers have had increasing success in lowering barriers to entry in the marketplace. The Act created a streamlined process, the Abbreviated New Drug Application...

Sunstein Kann Murphy and Timbers: Supreme Court Stands to Reshape Patent Law for the Life Sciences

By Nancy Wilker, Ph.D . A member of the Life Sciences Practice Group Two thousand thirteen may end up being the year of life sciences patent law at the Supreme Court. In the last three months, the court has agreed to hear three biotech/pharma cases, the outcomes of which will have sweeping implications...